SCHEMBL23360714

SCHEMBL23360714

C[C@@H]1CN(c2ccc([N+](=O)[O-])c(N)c2)C[C@@H](C)O1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.61
MAPT P10636 8/20 0.60
SIRT6 Q8N6T7 2/20 0.60
RECQL P46063 1/20 0.57
RAB9A P51151 1/20 0.54
ALDH1A1 P00352 7/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
HPGD P15428 2/20 0.46
GAA P10253 1/20 0.45
TSHR P16473 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
HTR7 P34969 1/20 0.44
L3MBTL1 Q9Y468 3/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 2/20 0.41
PKM P14618 1/20 0.41
MEN1 O00255 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3603190 1.00 LMNA (0.61) LMNAMAPTSIRT6RECQLRAB9A
SCHEMBL5054816 1.00 LMNA (0.61) LMNAMAPTSIRT6RECQLRAB9A
SCHEMBL30168945 1.00 LMNA (0.61) LMNAMAPTSIRT6RECQLRAB9A
SCHEMBL21032675 1.00 LMNA (0.61) LMNAMAPTSIRT6RECQLRAB9A
SCHEMBL24519809 0.84 LMNA (0.59) LMNAMAPTSIRT6RECQLRAB9A
SCHEMBL12813151 0.84 LMNA (0.59) LMNAMAPTSIRT6RECQLRAB9A
SCHEMBL20293508 0.83 MAPT (0.64) LMNAMAPTSIRT6RECQLALDH1A1
SCHEMBL23072835 0.83 MAPT (0.64) LMNAMAPTSIRT6RECQLALDH1A1
SCHEMBL16054939 0.83 LMNA (0.61) LMNAMAPTSIRT6RECQLALDH1A1
SCHEMBL30565923 0.83 MAPT (0.64) LMNAMAPTSIRT6RECQLALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691970-B2 Pyrazolopyridinone compounds JANSSEN PHARMACEUTICA NV (BE) 2023-07-04 US disclosed
US-11691970-B2 Pyrazolopyridinone compounds JANSSEN PHARMACEUTICA NV (BE) 2023-07-04 US disclosed
US-11691970-B2 Pyrazolopyridinone compounds JANSSEN PHARMACEUTICA NV (BE) 2023-07-04 US disclosed
EP-3713941-B1 PYRAZOLOPYRIDINONE COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2022-06-22 EP disclosed
US-20210147411-A1 PYRAZOLOPYRIDINONE COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2021-05-20 US disclosed
US-20210147411-A1 PYRAZOLOPYRIDINONE COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2021-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210147411-A1 PYRAZOLOPYRIDINONE COMPOUNDS FGFR1, FGFR3, FGFR2 LMNA 4095/4885MAPT 1516/4885SIRT6 2510/4885
US-11691970-B2 Pyrazolopyridinone compounds FGFR1, FGFR3, FGFR2 LMNA 4095/4885MAPT 1516/4885SIRT6 2510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.